Drug Profile
Research programme: radiolabelled carbonic anhydrase IX inhibitors - Progenics Pharmaceuticals
Alternative Names: 99mTc-MIP-1505; 99mTc/Re(CO)3 labelled benzenesulfonamide conjugates for molecular imaging of carbonic anhydrase IX - Progenics; Hypoxia-imaging radiopharmaceutical - Progenics; MIP-1267; MIP-1505; Small molecular inhibitor of CA IX radiolabelled with 99mTc - Progenics; Small-molecule benzenesulfonamide (BzSA) CA-IX inhibitors - ProgenicsLatest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Benzene derivatives; Radiopharmaceutical diagnostics; Small molecules; Sulfonamides
- Mechanism of Action Carbonic anhydrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals